Streetbeat News

Earnings

MRSN

Mersana Therapeutics reported Q2 earnings per share (EPS) of $(0.47), beating the analyst consensus estimate of $(0.50) by 6%. This is a 14.55% increase over losses from the same period last year. The company also reported quarterly sales of $10.65M, beating the analyst consensus estimate of $8.45M by 26.08%. This is a 148.69% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:19 pm

NVEE

NV5 has acquired Red Technologies, a move that strengthens its data center and mission critical services in the Asia Pacific region. The acquisition was made with a combination of cash and stock and is expected to be immediately accretive to NV5's earnings.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:18 pm

CRBP

Corbus Pharmaceuticals reported Q2 losses of $(2.05) per share, beating the analyst consensus estimate of $(3.10) by 33.87 percent. This represents a 2.38 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:17 pm

NUWE

Nuwellis reported Q2 earnings per share (EPS) of $(3.65), beating the analyst consensus estimate of $(4.02) by 9.2%. However, the company's quarterly sales of $2.07 million missed the estimate of $2.19 million by 5.48%. Compared to the same period last year, the EPS increased by 91.1% while sales decreased by 6.46%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:16 pm

TPG

TPG reported Q2 earnings of $0.26 per share, missing the analyst consensus estimate of $0.34 by 23.53%. This is a 43.48% decrease from the same period last year. However, the company reported quarterly sales of $327.10 million, beating the analyst consensus estimate of $295.21 million by 10.80%. This is a 12.81% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:10 pm

FSTR

L.B. Foster has updated its 2023 financial guidance due to improved profitability in its year-to-date results. The company now expects adjusted EBITDA to range between $28 million to $32 million, up from the previous estimate of $27 million to $31 million. Despite the impact of divestitures, net sales guidance for 2023 remains unchanged at between $520 million to $550 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:09 pm

TOVX

Theriva Biologics reported Q2 losses of $(0.34) per share, a 9.68% decrease from $(0.31) per share in the same period last year. The company's cash balance stands at $34.2M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:07 pm

GBLI

Global Indemnity (NASDAQ:GBLI) reported Q2 earnings of $0.50 per share, beating the analyst consensus estimate of $0.45 by 11.11%. This is a 316.67% increase from the same period last year. However, the company's quarterly sales of $141.89 million missed the analyst consensus estimate of $146.00 million by 2.81%, a 4.04% decrease from last year.

Portfolio Pulse from sunil@benzinga.com

August 08, 2023 | 12:07 pm

CNSL

Consolidated Communications has reaffirmed its 2023 adjusted EBITDA forecast of $310M-$330M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:05 pm

CTV

Innovid (NYSE:CTV) reported Q2 adjusted EPS of $(0.03), in line with analyst consensus. This is a 200% decrease from the same period last year. Quarterly sales were $34.55M, beating the $32.00M estimate by 7.96%. This is a 4.41% increase from the same period last year.

Portfolio Pulse from totan@benzinga.com

August 08, 2023 | 12:05 pm